CRIS Current Research Information System

MONGIORGI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.656
EU - Europa 3.344
AS - Asia 1.559
AF - Africa 290
Continente sconosciuto - Info sul continente non disponibili 17
SA - Sud America 11
OC - Oceania 8
Totale 8.885
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.631
IT - Italia 1.023
GB - Regno Unito 631
SE - Svezia 500
CN - Cina 491
DE - Germania 445
SG - Singapore 417
VN - Vietnam 320
RU - Federazione Russa 161
IN - India 131
TG - Togo 118
IE - Irlanda 107
FR - Francia 94
JP - Giappone 71
CI - Costa d'Avorio 69
NG - Nigeria 50
BG - Bulgaria 49
ZA - Sudafrica 49
AT - Austria 46
EE - Estonia 46
UA - Ucraina 42
HR - Croazia 41
CH - Svizzera 40
JO - Giordania 35
FI - Finlandia 34
BE - Belgio 30
KR - Corea 28
CA - Canada 25
NL - Olanda 20
EU - Europa 15
ID - Indonesia 14
IR - Iran 11
TR - Turchia 10
PL - Polonia 9
GR - Grecia 7
UZ - Uzbekistan 6
AU - Australia 5
LB - Libano 5
LT - Lituania 5
BR - Brasile 4
HK - Hong Kong 4
RO - Romania 4
BD - Bangladesh 3
IL - Israele 3
MY - Malesia 3
NZ - Nuova Zelanda 3
UY - Uruguay 3
DK - Danimarca 2
ES - Italia 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
SS - ???statistics.table.value.countryCode.SS??? 2
AE - Emirati Arabi Uniti 1
BO - Bolivia 1
CL - Cile 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EG - Egitto 1
HU - Ungheria 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MM - Myanmar 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
Totale 8.885
Salva come PNG Salva come JPEG
Città #
Southend 560
Chandler 456
Bologna 378
Fairfield 367
Singapore 347
Ashburn 289
Santa Clara 262
Ann Arbor 223
Houston 173
Wilmington 168
Woodbridge 156
Princeton 143
Seattle 137
Cambridge 125
Lomé 118
Dong Ket 111
Dublin 107
Boardman 100
Abidjan 69
Padova 63
Westminster 56
Milan 55
Nanjing 54
Abeokuta 50
Sofia 49
Berlin 45
Frankfurt am Main 40
Tokyo 40
Redwood City 39
Jinan 38
Beijing 37
New York 36
Vienna 36
Amman 35
Bern 33
Saint Petersburg 33
Turin 33
Helsinki 31
Medford 31
Bremen 30
Brussels 30
Changsha 26
Redmond 26
Florence 25
Moscow 25
San Diego 25
Nanchang 24
Shenyang 24
Guangzhou 21
Parma 20
Sejong 18
Hebei 17
London 16
Shanghai 15
Des Moines 14
Toronto 14
Udine 14
Jakarta 13
Norwalk 13
Dearborn 12
Falkenstein 12
Falls Church 12
Jiaxing 12
Amsterdam 11
Hangzhou 11
Rome 11
Tappahannock 11
Yubileyny 11
Los Angeles 9
Modena 9
Valsamoggia 9
Bühl 8
Düsseldorf 8
Haikou 8
Lanzhou 8
Mountain View 8
Nuremberg 8
Paris 8
Ravenna 8
Tianjin 8
Zhengzhou 7
Buffalo 6
Cesena 6
Council Bluffs 6
Jacksonville 6
Kunming 6
Marzabotto 6
Ottawa 6
Phoenix 6
Vicenza 6
Yuseong-gu 6
Chicago 5
Forlì 5
Granarolo dell'Emilia e Viadagola 5
Hefei 5
Imola 5
Sacramento 5
San Francisco 5
Taizhou 5
Verona 5
Totale 5.847
Salva come PNG Salva come JPEG
Nome #
Cell signaling pathways in autosomal-dominant leukodystrophy (ADLD): the intriguing role of the astrocytes 257
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 221
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 214
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 201
Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and β-thalassemia 189
Nuclear phosphoinositides: Their regulation and roles in nuclear functions 176
Inositide-Dependent Nuclear Signalling in Health and Disease 172
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 167
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 166
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 166
Impact of phospholipase C β1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness 166
Nuclear inositide signaling and cell cycle 162
PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis 160
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 159
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 155
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 152
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 150
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 149
Nuclear Inositide Signaling via Phospholipase C 140
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 137
Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes 136
Protein kinase C involvement in cell cycle modulation 131
Near-peer teaching in human anatomy from a tutors’ perspective: An eighteen-year-old experience at the university of Bologna 131
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 130
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 129
Nuclear phospholipase C beta1 and cellular differentiation. 128
Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology 125
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 125
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 124
Nuclear inositide signaling in myelodysplastic syndromes. 121
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 121
Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C 120
Lamin B1 accumulation’s effects on autosomal dominant leukodystrophy (ADLD): Induction of reactivity in the astrocytes 120
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 118
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 116
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 115
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 115
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 114
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 113
The wide and growing range of lamin B‑related diseases: from laminopathies to cancer 113
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 112
Role of PLCγ1 in the modulation of cell migration and cell invasion in glioblastoma 112
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 111
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 109
Recent advances in MDS mutation landscape: Splicing and signalling 109
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 108
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 106
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 106
Phosphoinositide-dependent signaling in cancer: A focus on phospholipase C isozymes 105
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 105
Exploring the controversial role of PI3K signalling in CD4+ regulatory T (T-Reg) cells 104
null 103
The whole body donation program at the university of Bologna: A report based on the experience of one of the oldest university in Western world 103
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 101
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 99
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 96
Subcellular localization relevance and cancer-associated mechanisms of diacylglycerol kinases 96
null 95
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 91
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK MYELODYSPLASTIC SYNDROMES 87
Epigenetic Regulation of Nuclear PI-PLCbeta1 Signalling Pathway in Low-Risk MDS Patients During Azacitidine Treatment 87
ROLE OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS ON EPO-INDUCED EYTHROID DIFFERENTIATION IN LOW-RISK MDS PATIENTS 85
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 84
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 84
Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia 84
GENE EXPRESSION OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS IN MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 83
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 81
null 81
Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula 80
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 79
null 72
null 71
Lamin B1 as a key modulator of the developing and aging brain 53
Understanding the Ultra-Rare Disease Autosomal Dominant Leukodystrophy: an Updated Review on Morpho-Functional Alterations Found in Experimental Models 35
Emerging Roles of Phospholipase C Beta Isozymes as Potential Biomarkers in Cardiac Disorders 35
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 34
Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor Cells 28
Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation 27
Current therapy and new drugs: A road to personalized treatment of myelodysplastic syndromes 24
PKR is activated in MDS patients and its subcellular localization depends on disease severity. 20
Totale 9.189
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.738
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.738
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020696 0 0 0 0 0 0 0 166 234 100 97 99
2020/20211.123 199 54 39 33 26 53 65 67 104 47 43 393
2021/20221.707 134 33 81 140 136 77 51 95 74 279 325 282
2022/20232.031 180 265 110 310 169 159 120 151 291 29 130 117
2023/2024840 51 101 82 83 98 121 28 41 74 73 49 39
2024/20251.472 121 272 188 134 350 130 187 90 0 0 0 0
Totale 9.189